Literature DB >> 10937773

Serological analysis of specific IgA to Chlamydia pneumoniae: increased sensitivity of IgA antibody detection using prolonged incubation and high antigen concentration.

J Gnarpe1, A Sparr, J Nääs, A Lundbäck.   

Abstract

The microimmunofluorescence technique (MIF) is recognized as the only test hitherto allowing discrimination between different Chlamydia species and is considered to be the reference method for serology. This method was developed for the detection of IgG and IgM antibodies only. We investigated the effects of some test parameters on the ability of MIF to detect Chlamydia pneumoniae IgA. These parameters were the time needed for binding of serum IgA to C. pneumoniae antigen and the effect of antigen concentration on the outcome of IgA antibody testing. It was found that the most sensitive MIF tests for the detection of serum IgA antibodies were those in which an overnight incubation of sera with antigen slides containing high concentrations of chlamydial elementary bodies was employed. The number of patients with chronic infections found to have elevated IgA titers was increased by 25% using longer incubation times for the antibody-antigen reaction. Thirty-two sera from patients with coronary artery disease and confirmed chronic C. pneumoniae infection were used to compare antigen slides with low and high concentrations of elementary bodies with respect to IgA levels; 31/32 patients were found to have specific IgA antibodies to C. pneumoniae using the high antigen concentration, as opposed to only 22/32 patients using the low antigen concentration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10937773     DOI: 10.1034/j.1600-0463.2000.d01-68.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  5 in total

1.  Measurement of Chlamydia pneumoniae-specific immunoglobulin A (IgA) antibodies by the microimmunofluorescence (MIF) method: comparison of seven fluorescein-labeled anti-human IgA conjugates in an in-house MIF test using one commercial MIF and one enzyme immunoassay kit.

Authors:  Mika Paldanius; Aini Bloigu; Maija Leinonen; Pekka Saikku
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

2.  Chlamydophila pneumoniae infection and cardiovascular disease.

Authors:  Rajnish Joshi; Bidita Khandelwal; Deepti Joshi; Om Prakash Gupta
Journal:  N Am J Med Sci       Date:  2013-03

3.  Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma.

Authors:  David L Hahn; Mary Beth Plane; Olaimatu S Mahdi; Gerald I Byrne
Journal:  PLoS Clin Trials       Date:  2006-06-30

4.  Detection of Chlamydia pneumoniae on cytospin preparations from bronchoalveolar lavage in COPD patients and in lung tissue from advanced emphysema.

Authors:  Eva Brandén; Judy Gnarpe; Gunnar Hillerdal; Lotta Orre; C Magnus Sköld; Magnus Löfdahl; Hirsh Koyi; Göran Tornling
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

5.  Evaluation and optimization of a commercial enzyme linked immunosorbent assay for detection of Chlamydophila pneumoniae IgA antibodies.

Authors:  Olfa Frikha-Gargouri; Radhouane Gdoura; Abir Znazen; Nozha Ben Arab; Jalel Gargouri; Mounir Ben Jemaa; Adnene Hammami
Journal:  BMC Infect Dis       Date:  2008-07-26       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.